IL22 and inflammatory bowel disease: We chose MSCsPPsiIL‐22#2 for the following experiments due to its lower expression of IL‐22, and confirmed that MSCsPPsiIL‐22#2 showed less effective therapeutic effects in murine IBD models than MSCsPPcon on the basis of colitis evaluation parameters, including body weight, DAI, colon length, histological scores and inflammatory cytokines.